Irreversible electroporation for nonthermal tumor ablation in patients with hepatocellular carcinoma: initial clinical experience in Japan

Japanese Journal of Radiology

Volumn 33, Issue 7, 2015, Pages 424-432

  Sugimoto, Katsutoshi ^a   Moriyasu, Fuminori ^a   Kobayashi, Yoshiyuki ^a   Saito, Kazuhiro ^a   Takeuchi, Hirohito ^a   Ogawa, Saori ^a   Ando, Mayumi ^a   Sano, Takatomo ^a   Mori, Toshifumi ^a   Furuichi, Yoshihiro ^a   Nakamura, Ikuo ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Ablation; Hepatocellular carcinoma; Irreversible electroporation (IRE)

Indexed keywords

GADOXETIC ACID; PERFLUBUTANE; PROPOFOL; REMIFENTANIL;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; ECHOGRAPHY; ELECTROPORATION; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; IMAGE ANALYSIS; IRREVERSIBLE ELECTROPORATION; IRREVERSIBLE ELECTROPORATION DEVICE; JAPAN; LABORATORY TEST; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MICROBUBBLE; MIDDLE AGED; MINIMALLY INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PATIENT SAFETY; PATIENT SATISFACTION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RADIOFREQUENCY ABLATION DEVICE; TREATMENT OUTCOME; TUMOR ABLATION; TUMOR VOLUME; ULTRASOUND TRANSDUCER; ABLATION THERAPY; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; GENERAL ANESTHESIA; LIVER NEOPLASMS; PROCEDURES; PROSPECTIVE STUDY;

ABLATION TECHNIQUES; AGED; ANESTHESIA, GENERAL; CARCINOMA, HEPATOCELLULAR; ELECTROPORATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; ULTRASONOGRAPHY;

EID: 84937971636     PISSN: 18671071     EISSN: 1867108X     Source Type: Journal    
DOI: 10.1007/s11604-015-0442-1     Document Type: Article

References (20)

1. Davalos RV, Mir IL, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng. 2005;33:223–31.
2. Lee EW, Loh CT, Kee ST. Imaging guided percutaneous irreversible electroporation: ultrasound and immunohistological correlation. Technol Cancer Res Treat. 2007;6:287–94.
3. Martin RC, Philips P, Ellis S, Hayes D, Bagla S. Irreversible electroporation of unresectable soft tissue tumors with vascular invasion: effective palliation. BMC Cancer. 2014;14:540.
4. Cheung W, Kavnoudias H, Roberts S, Szkandera B, Kemp W, Thomson KR. Irreversible electroporation for unresectable hepatocellular carcinoma: initial experience and review of safety and outcomes. Technol Cancer Res Treat. 2013;12:233–41.
5. Martin RC 2nd, McFarland K, Ellis S, Velanovich V. Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival. Ann Surg Oncol. 2013;20:S443–9.
6. Thomson KR, Cheung W, Ellis SJ, Federman D, Kavnoudias H, Loader-Oliver D, et al. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol. 2011;22:611–21.
7. Valerio M, Dickinson L, Ali A, Ramachandran N, Donaldson I, Freeman A, et al. A prospective development study investigating focal irreversible electroporation in men with localised prostate cancer: Nanoknife Electroporation Ablation Trial (NEAT). Contemp Clin Trials. 2014;39:57–65.
8. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, et al. HCC Expert Panel of Japan Society of Hepatology. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis. 2011;29:339–64.
9. International Working Party. Terminology of nodular hepatocellular lesions. Hepatology. 1995;22:983–93.
10. Cardella JF, Kundu S, Miller DL, Millward SF, Sacks D. Society of Interventional Radiology. Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol. 2009;20:S189–91.
11. Sugimoto K, Moriyasu F, Kobayashi Y, Imai Y. Assessment of irreversible electroporation ablation zone using Kupffer-phase contrast-enhanced ultrasound (CEUS) images with Sonazoid. J Med Ultrason. 2014;41:531–2.
12. Sugimoto K, Moriyasu F, Kobayashi Y, Kasuya K, Nagakawa Y, Tsuchida A, et al. Assessment of various types of US findings after irreversible electroporation in porcine liver: comparison with radiofrequency ablation. J Vasc Interv Radiol. 2015;26:279–87.
13. Guo Y, Zhang Y, Nijm GM, Sahakian AV, Yang GY, Omary RA, et al. Irreversible electroporation in the liver: contrast-enhanced inversion-recovery MR imaging approaches to differentiate reversibly electroporated penumbra from irreversibly electroporated ablation zones. Radiology. 2011;258:461–8.
14. Qin Z, Jiang J, Long G, Lindgren B, Bischof JC. Irreversible electroporation: an in vivo study with dorsal skin fold chamber. Ann Biomed Eng. 2013;41:619–29.
15. Moriyasu F, Itoh K. Efficacy of perflubutane microbubble-enhanced ultrasound in the characterization and detection of focal liver lesions: phase 3 multicenter clinical trial. AJR Am J Roentgenol. 2009;193:86–95.
16. Sugimoto K, Moriyasu F, Shiraishi J, Saito K, Taira J, Saguchi T, et al. Assessment of arterial hypervascularity of hepatocellular carcinoma: comparison of contrast-enhanced US and gadoxetate disodium-enhanced MR imaging. Eur Radiol. 2012;22:1205–13.
17. Wilson SR, Burns PN. Microbubble-enhanced US in body imaging: what role? Radiology. 2010;257:24–39.
18. Rhim H, Lee MH, Kim YS, Choi D, Lee WJ, Lim HK. Planning sonography to assess the feasibility of percutaneous radiofrequency ablation of hepatocellular carcinomas. AJR Am J Roentgenol. 2008;190:1324–30.
19. Kunishi Y, Numata K, Morimoto M, Okada M, Kaneko T, Maeda S, et al. Efficacy of fusion imaging combining sonography and hepatobiliary phase MRI with Gd-EOB-DTPA to detect small hepatocellular carcinoma. AJR Am J Roentgenol. 2012;198:106–14.
20. Kingham TP, Karkar AM, D’Angelica MI, Allen PJ, Dematteo RP, Getrajdman GI, et al. Ablation of perivascular hepatic malignant tumors with irreversible electroporation. J Am Coll Surg. 2012;215:379–87.